Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative…

Overview of attention for article published in Journal of Clinical Oncology, February 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 2 news outlets
twitter: 34 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 46 Mendeley

So far, Altmetric has seen 37 X posts from 34 X users, with an upper bound of 274,315 followers.

RT @JCO_ASCO: 🗣️ Patient reported outcomes in the OlympiA trial show that olaparib was well-tolerated compared to placebo in pts w gBRCA1/2…

🗣️ Patient reported outcomes in the OlympiA trial show that olaparib was well-tolerated compared to placebo in pts w gBRCA1/2 #breastcancer: https://t.co/WSkkjtpLHN #bcsm @nrgonc

RT @DFCI_BreastOnc: New pub in @JCO_ASCO: Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuva…

RT @ElisaAgostinett: In @JCO_ASCO Patient Reported Outcomes from #OlympiA Patients treated with olaparib or placebo had similar functional…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 33 additional X posts.